About | EpimAb

Who We Are

EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients.

Promising Pipeline Derived From In-House Research

Preclinical and clinical assets address global unmet medical needs

Sustainable first-/best-in-class pipeline with 3 candidates in the clinic

Novel and Proprietary Bispecific Antibody Technology Platform

World-class innovative BsAb platform with strong IP

Rapid and proven bispecific antibody development process that is comparable to that for typical monoclonal antibodies

Seasoned and Well-rounded Management Team with Global Track Records

Dr. Chengbin Wu is a top expert in the BsAb area with a well-established track record

Team includes other industry veterans with complementary experiences from early discovery, clinical development, CMC, to business development and financing

EpimAb Aims to Redefine Bispecific Antibodies (BsAb)